Evidence mapPaperPMID 27423262Full record

SynthesisLancet (London, England)2016

Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.

Global BMI Mortality Collaboration, Emanuele Di Angelantonio, Shilpa Bhupathiraju, David Wormser, Pei Gao, Stephen Kaptoge, Amy Berrington de Gonzalez, Benjamin Cairns, Rachel Huxley, Chandra Jackson and 51 more

4 registry-linked trialsAbstract readMeta-AnalysisMulticenter Study
In one paragraph

Synthesis in Lancet (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 1,283 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,283citing papers in PubMed, 12 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05574439 phase4completedstarted 2022, after this paper: background citation

Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study

Ran2022Enrolled246Registered outcomes54Posted comparisons0ConditionsObesity, AdolescentArmsPlacebo (Semaglutide 3 mg/ml), Semaglutide 3 mg/ml, TCOC treatment
Open the trial in the graph
NCT03654105 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation

Multifactorial Intervention of Primary Prevention in High Risk Subjects: a Randomized Trial

TypeinterventionalSponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2019 to 2026Enrolled2,000ConditionsInflammation, Smoking Cessation, Diet Modification, Physical ActivityArmsCytisine, Acetylsalicylic acid, Diet Modification and Physical Activity Increase, early lung cancer detection, spirometry with CO test
NCT06934681 narecruitingnot on this mapstarted 2025, after this paper: background citation

Impact of a Structured Physical Exercise Program on Body Composition in Morbid Obesity: A Randomized Controlled Trial

TypeinterventionalSponsorInstituto de Investigacion Sanitaria La FeRan2025 to 2029Enrolled72ConditionsMorbid Obesity, Bariatric Surgery, TelerehabilitationArmsUsual Care Group, Controlled exercise with telerehabilitation
NCT07095543 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Feasibility, Implementation, and Efficacy of a Plant-based Online Weight Loss Through Education and Resources Program and Study (POWER Study)

TypeinterventionalSponsorPhysicians Committee for Responsible MedicineRan2025 to 2028Enrolled100ConditionsType 2 Diabetes, Overweight and Obese AdultsArmsLow-fat, vegan diet
3 · Its place in the literature

Who cites it

1,283 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Polygenic Risk and Nutrient Intake Interactions on Obesity Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Potential lipid-lowering effects ofFrontiers in nutrition · 2026
    Trial
  18. Trial
  19. Trial
  20. Trial

1,223 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

61 authors.

Global BMI Mortality Collaboration
Emanuele Di Angelantonio
Shilpa Bhupathiraju
David Wormser
Pei Gao
Stephen Kaptoge
Amy Berrington de Gonzalez
Benjamin Cairns
Rachel Huxley
Chandra Jackson
Grace Joshy
Sarah Lewington
JoAnn Manson
Neil Murphy
Alpa Patel
Jonathan Samet
Mark Woodward
Wei Zheng
Maigen Zhou
Narinder Bansal
Aurelio Barricarte
Brian Carter
James Cerhan
George Smith
Xianghua Fang
Oscar Franco
Jane Green
Jim Halsey
Janet Hildebrand
Keum Jung
Rosemary Korda
Dale McLerran
Steven Moore
Linda O'Keeffe
Ellie Paige
Anna Ramond
Gillian Reeves
Betsy Rolland
Carlotta Sacerdote
Naveed Sattar
Eleni Sofianopoulou
June Stevens
Michael Thun
Hirotsugu Ueshima
Ling Yang
Young Yun
Peter Willeit
Emily Banks
Valerie Beral
Zhengming Chen
Susan Gapstur
Marc Gunter
Patricia Hartge
Sun Jee
Tai-Hing Lam
Richard Peto
John Potter
Walter Willett
Simon Thompson
John Danesh
Frank Hu

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI GREENBERG, ANDREW S, PERISSI, VALENTINA · 1992 to 2021
$25.0M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Social and Environmental Determinants of Health EquityZIAES103325 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI JACKSON, CHANDRA · 2017 to 2025
$12.7M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Sleep Duration, Childhood Energy Balance, and Insulin Resistance in AdolescenceU54CA155626 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI STAMPFER, MEIR · 2011 to 2015
$9.6M
BIOCHEMICAL AND GENETIC MARKERS OF TYPE 2 DIABETES RISKR01DK058845 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, FRANK B · 2001 to 2013
$7.8M
Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
British Heart Foundation RG/08/014/24067British Heart Foundation RG/13/13/30194Cancer Research UK 16491Medical Research Council G0700474Medical Research Council G0800270Medical Research Council G9900923Medical Research Council MC_QA137853Medical Research Council MC_UU_12013/1Medical Research Council MR/K02700X/1Medical Research Council MR/L003120/1NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS U54 CA155626NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182910NIDDK NIH HHS DK58845NIDDK NIH HHS P30 DK046200NIDDK NIH HHS R01 DK058845
6 · The paper itself

Abstract

backgroundOverweight and obesity are increasing worldwide. To help assess their relevance to mortality in different populations we conducted individual-participant data meta-analyses of prospective studies of body-mass index (BMI), limiting confounding and reverse causality by restricting analyses to never-smokers and excluding pre-existing disease and the first 5 years of follow-up.

methodsOf 10 625 411 participants in Asia, Australia and New Zealand, Europe, and North America from 239 prospective studies (median follow-up 13·7 years, IQR 11·4-14·7), 3 951 455 people in 189 studies were never-smokers without chronic diseases at recruitment who survived 5 years, of whom 385 879 died. The primary analyses are of these deaths, and study, age, and sex adjusted hazard ratios (HRs), relative to BMI 22·5-<25·0 kg/m(2).

findingsAll-cause mortality was minimal at 20·0-25·0 kg/m(2) (HR 1·00, 95% CI 0·98-1·02 for BMI 20·0-<22·5 kg/m(2); 1·00, 0·99-1·01 for BMI 22·5-<25·0 kg/m(2)), and increased significantly both just below this range (1·13, 1·09-1·17 for BMI 18·5-<20·0 kg/m(2); 1·51, 1·43-1·59 for BMI 15·0-<18·5) and throughout the overweight range (1·07, 1·07-1·08 for BMI 25·0-<27·5 kg/m(2); 1·20, 1·18-1·22 for BMI 27·5-<30·0 kg/m(2)). The HR for obesity grade 1 (BMI 30·0-<35·0 kg/m(2)) was 1·45, 95% CI 1·41-1·48; the HR for obesity grade 2 (35·0-<40·0 kg/m(2)) was 1·94, 1·87-2·01; and the HR for obesity grade 3 (40·0-<60·0 kg/m(2)) was 2·76, 2·60-2·92. For BMI over 25·0 kg/m(2), mortality increased approximately log-linearly with BMI; the HR per 5 kg/m(2) units higher BMI was 1·39 (1·34-1·43) in Europe, 1·29 (1·26-1·32) in North America, 1·39 (1·34-1·44) in east Asia, and 1·31 (1·27-1·35) in Australia and New Zealand. This HR per 5 kg/m(2) units higher BMI (for BMI over 25 kg/m(2)) was greater in younger than older people (1·52, 95% CI 1·47-1·56, for BMI measured at 35-49 years vs 1·21, 1·17-1·25, for BMI measured at 70-89 years; pheterogeneity<0·0001), greater in men than women (1·51, 1·46-1·56, vs 1·30, 1·26-1·33; pheterogeneity<0·0001), but similar in studies with self-reported and measured BMI.

interpretationThe associations of both overweight and obesity with higher all-cause mortality were broadly consistent in four continents. This finding supports strategies to combat the entire spectrum of excess adiposity in many populations.

fundingUK Medical Research Council, British Heart Foundation, National Institute for Health Research, US National Institutes of Health.

Indexed as

Body Mass IndexCause of DeathAdultAgedAsiaAustraliaEuropeFemaleHumansLinear ModelsMaleMiddle AgedMortalityNew ZealandNorth AmericaOverweight

Identifiers

PMID27423262
PMCPMC4995441

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.